Navigation Links
Watson Confirms NIASPAN(R) Patent Challenge
Date:3/19/2012

PARSIPPANY, N.J., March 19, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Niacin Extended-release Tablets, 500 mg and 1000 mg. Watson's ANDA products are generic versions of Abbott Laboratories' NIASPAN®.

Abbott Laboratories and Abbott Respiratory LLC filed suit against Watson on March 16, 2012, in the United States District Court for the District of Delaware seeking to prevent Watson from commercializing its ANDA products prior to the expiration of U.S. Patent Nos. 6,080,428 and 6,469,035.  The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months from the date the plaintiffs received notice of Watson's ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

For the twelve months ending January 31, 2012, NIASPAN® had total U.S. sales of approximately $1.2 billion according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

NIASPAN® is a registered trademark of Abbott Respiratory LLC.

CONTACTS:

Investors:

Patty Eisenhaur
(862) 261-8141

Media:
Charlie Mayr
(862) 261-8030

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... -- OMS Supply, a large provider of oral surgery supplies ... recent launching of their new company website. The OMS ... enhance the user experience and enable practitioners to browse ... --> --> Despite the fact that ... in early 2016, they have already made an unprecedented ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
(Date:2/12/2016)... February 12, 2016 ... titled Chronic Inflammation Global Clinical Trials Review, H2, ... the global clinical trials landscape along with top ... Region, Country (G7 & E7), Trial Status, Trial ... reviews top companies involved and enlists all trials ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed ... p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed ... pharmaceutical products, garnering increased attention from all stakeholders in the development of new ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a ... closed for the ISE Southeast Awards 2016. Finalists and winners of the ISE® ... Southeast Executive Forum and Awards Gala on March 15, 2016 at the Westin ...
(Date:2/12/2016)... ... ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined Governor Brian Sandoval, ... Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System yesterday to dedicate ... be the first Fisher House in Nevada, and will provide free lodging for families ...
(Date:2/12/2016)... ... , ... Erlanger Agency has announced a new partnership in its ongoing community ... on the fight against breast cancer, fundraising for a local woman named Carmen, who ... Carmen is a loving single mother of two boys who also serves as caregiver ...
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet ... RDH, and dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s ... professionals, donating their time and skills to help hundreds of uninsured and underinsured people ...
Breaking Medicine News(10 mins):